Compare DFLI & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFLI | ICCC |
|---|---|---|
| Founded | 2020 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.0M | 55.5M |
| IPO Year | N/A | 1987 |
| Metric | DFLI | ICCC |
|---|---|---|
| Price | $3.38 | $6.17 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $22.50 | N/A |
| AVG Volume (30 Days) | ★ 725.8K | 23.8K |
| Earning Date | 11-14-2025 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.26 |
| Revenue | ★ $57,783,000.00 | $27,769,304.00 |
| Revenue This Year | $17.85 | N/A |
| Revenue Next Year | $30.29 | N/A |
| P/E Ratio | ★ N/A | $24.65 |
| Revenue Growth | ★ 18.24 | 16.49 |
| 52 Week Low | $1.50 | $4.28 |
| 52 Week High | $26.20 | $7.60 |
| Indicator | DFLI | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 48.31 | 47.40 |
| Support Level | $3.50 | $6.15 |
| Resistance Level | $4.55 | $6.92 |
| Average True Range (ATR) | 0.35 | 0.31 |
| MACD | -0.17 | -0.06 |
| Stochastic Oscillator | 5.24 | 3.85 |
Dragonfly Energy Holdings Corp is a manufacturer of non-toxic deep cycle lithium-ion batteries that are designed to displace lead acid batteries in a number of different storage applications and end markets including RV, marine vessel, and solar and off-grid industries, with disruptive solid-state cell technology currently under development. The company's deep cycle lithium iron phosphate ("LFP") batteries provide numerous advantages compared to incumbent products, such as lead-acid batteries. LFP batteries are non-toxic and environmentally friendly, do not rely on scarce or controversial metals, and are a cost-effective storage solution.
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.